AUTHORS
Ziad Abuhelwa, MD, MPH, Amin Azem, MD2, Mohammad Hussaini, MD3, Celeste Bello, MD4, Samuel Benjamin Reynolds, MD5, Leidy Isenalumhe, MD, MS6, Supreet Kaur, MD7, Hayder Saeed, MD8, Lubomir Sokol, MD, PhD9, Bijal Shah, MD, MS10, Yumeng Zhang, MD11, Javier Pinilla-Ibarz, MD PhD12, Sameh Gaballa, MD13
AFFILIATIONS
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
ABSTRACT
Background
Accelerated CLL/SLL (aCLL/SLL) is a histologically defined subtype characterized by expanded or confluent proliferation centers (PCs) with high proliferative activity (Giné criteria). Although not recognized as a distinct entity in WHO-HAEM5 or ICC, aCLL/SLL is thought to occupy a clinical and biologic space between classic CLL/SLL and Richter transformation (RT). Available data derive from small retrospective cohorts spanning heterogeneous eras that largely predate BTK inhibitor (BTKi) and BCL2 inhibitor (BCL2i) therapy, and aCLL/SLL is not captured in contemporary CLL trials. We report one of the largest single-center aCLL/SLL cohorts in the targeted therapy era, characterizing clinicopathologic and molecular features, treatment patterns, and survival outcomes.
Methods
This single-center retrospective study included adults (≥18 years) with biopsy-confirmed aCLL/SLL (nodal or extranodal) at Moffitt Cancer Center through June 2026. Diagnoses were based on pathology reports describing aCLL/SLL using Giné criteria; patients with biopsy-proven RT at aCLL/SLL diagnosis were excluded. Overall survival (OS) was measured from aCLL/SLL diagnosis to death from any cause and progression-free survival (PFS) from start of first-line therapy after aCLL/SLL diagnosis to progression, transformation, or death. Kaplan–Meier estimates were compared by log-rank test; exploratory Cox models were adjusted for TP53 aberration (del(17p) by FISH and/or TP53 mutation by NGS). First-line therapy was classified as targeted (BTKi- or BCL2i-based) vs chemotherapy-based (including R/O-CHOP).
Results
Thirty-seven patients were identified. Median age at aCLL/SLL diagnosis was 68.6 years (IQR 57.9–77.1); 68% were male. Twenty-three (62%) had antecedent CLL/SLL that later accelerated (median time from CLL/SLL diagnosis to acceleration, 75.0 months; IQR 46.0–111.6) and 14 (38%) had de novo aCLL/SLL. Twenty-one (57%) were treatment-naïve at aCLL/SLL diagnosis, and 16 (43%) were previously treated. Among tested patients, IGHV was unmutated in 68% (19/28), complex karyotype (≥3 abnormalities) was present in 67% (10/15), and TP53 mutation/del(17p) was present in 24% (8/33).
Thirty-one patients (84%) received treatment after aCLL/SLL diagnosis. First-line therapy was BTKi-based in 16 (52%), chemotherapy-based in 10 (32%) [R/O-CHOP=3, FCR=3, BR=3, R-CP=1], BCL2i-based in 3 (10%) and 1 each (3%) received PI3K inhibitor or underwent allogenic stem cell transplant. Overall, 27 (87%) received a novel agent at some point and 4 (13%) received chemotherapy-based regimens exclusively.
At a median follow-up of 27.6 months, median OS was 104.2 months (95% CI, 23.9–NR) and 2-year OS was 67.6% (14 patients at risk). OS was inferior with unmutated IGHV (median 104.2 vs NR months; p=0.026) and numerically shorter with TP53 mutation/del(17p), though did not reach statistical significance. OS did not differ significantly by de novo vs antecedent aCLL/SLL, treatment-naïve vs previously treated status, or first-line therapy class.
Among 31 treated patients, median PFS was 21.0 months (95% CI, 5.9–80.0) and 2-year PFS was 45.8%. PFS was numerically but not significantly shorter with TP53 aberration and unmutated IGHV and did not differ by de novo vs antecedent disease or treatment-naïve vs previously treated status. First-line chemotherapy-based therapy was associated with inferior PFS vs targeted therapy in unadjusted (HR 2.99; 95% CI 1.07–8.35; p=0.036) and TP53-adjusted analyses (HR 3.44; 95% CI 1.14–10.35; p=0.028). Only 3 (8%) had transformation, 1 large cell and 2 prolymphocytic transformations.
Conclusion
In this contemporary single-center cohort, aCLL/SLL frequently harbored high-risk features, including unmutated IGHV, complex karyotype, and TP53 aberration. First-line chemotherapy-based therapy was associated with inferior PFS compared with targeted therapy; given the retrospective design, small sample size, and probable confounding by indication and calendar era, this observation is hypothesis-generating but supports CLL-directed targeted therapy rather than lymphoma-directed regimens when RT has been excluded. Prospective incorporation of PC morphology and Ki-67 into CLL trials is needed to better define the biology, prognosis, and optimal management of aCLL/SLL.
DISCLOSURES
Ziad Abuhelwa, MD, MPH: No relevant conflicts of interest to declare.